Amgen Inc.

Holly L Deak

Karina Romero

Ning Xi

Matthew W Martin

Craig E Masse

Andrew Stewart Tasker

Joseph L Kim

Jean-Christophe P Harmange

Hanh Nho Nguyen

Stephanie Geuns-Meyer

Philip R Olivieri

Vinod Francis Patel

Brian K Albrecht

Jean E Bemis

Brian Lewis Hodous

Victor J Cee

Laurie B Schenkel

Isaac E Marx

Matthew M Weiss

Ryan D White

Steven F Bellon

Russell Graceffa

Mark Henry Norman

Anthony B Reed

Nobuko Nishimura

Robert Michael Rzasa

Xiaotian Zhu

Yuan Cheng

Kevin Chao Yang

Longbin Liu

Shon Booker

Liping H Pettus

Shimin Xu

Dawei Zhang

Charles Kreiman

Thomas Dineen

Erin F DiMauro

Stuart C Chaffee

Paul A Tempest

Nuria A Tamayo

Angel Guzman-Perez

Aaron C Siegmund

Daniel La

Alessandro Boezio

James Richard Falsey

Adrian Leonard Smith

Jason Brooks Human

Gregory J Habgood

Nick A Paras

Zihao Hua

Bradley J Herberich

Yunxin Y Bo

Partha P Chakrabarti

Guo-Qiang Cao

Bingfan Du

Emily Anne Peterson

Kathleen Panter

Rebecca E Johnson

Marian C Bryan

Nagasree Chakka

Howard Bregman

Hongbing Huang

Christiane Boezio

Katrina Woodin Copeland

William H Buckner

Kristin L Andrews

Maya C Thaman

James R Coats

Mathew Martin

Kelvin Sham

Phillip R Olivieri

Kate Panter

Philipp R Olivieri

Brian L Houdous

Stephanie D Guens-Meyer

Jason B Human

David C Mcgowan

Susan Ann Tomlinson

Frenel F Demorin

Guo-Giang Cao

John L Buchanan

Vinod F Patel

Laurie Schenkel

Erin F Dimauro

Stephanie D Geuns-Meyer

Stephanie D Geuns-meyer

The present invention provides compounds of Formula I or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention. 

Bicyclic sulfonamide compounds as sodium channel inhibitors

The present invention relates to chemical compounds having a general formula I wherein A, L, R, Rand n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds and methods of treating disease states related to the activity of Aurora kinase.

Aurora kinase modulators and methods of use

The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7.  The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.

Bicyclic aryl and heteroaryl sodium channel inhibitors

The present invention relates to chemical compounds having a general formula I wherein A, B, D, E, G, Hand Rare defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other proliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of protein kinases.

Protein kinase modulators and method of use

The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein Q, X, X, Rand Z are as defined herein. 

Inhibitors of PI3 kinase

The present invention relates to chemical compounds having a general formula I wherein A, A, C, C, D, L, L, Z and R, R, R, Rand Rare defined herein, which are capable of modulating Aurora kinase protein activity, thereby influencing various disease states and conditions related to the activities of Aurora kinase proteins. For example, the compounds are capable of influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, processes of preparing compounds of the invention, synthetic intermediates and methods of treatment of conditions related to the activity of Aurora kinase.

Aurora kinase modulators and method of use

The present invention relates to chemical compounds having a general formula I wherein A, D', L, L, R, Rand n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

The present invention relates to chemical compounds having a general formula I wherein A, B, D, E, G, Hand Rare defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other poliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of protein kinases.

The present invention relates to chemical compounds having a general formula I wherein A, B, C, C, D, L, Land Rare defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Tie-2 and Aurora kinase enzymes thereby influencing angiogenesis and the process of cell cycle and cell proliferation, respectively, to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of various protein kinases.

Multi-cyclic compounds and method of use

Growing community of inventors

Brookline, MA, United States of America

Holly L Deak